| ￥3300 | |
| Z05951-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity |
> 95% as determined by BisTris PAGE > 90% as determined by HPLC |
|
| Endotoxin Level | Less than 1EU per μg by the LAL method. | |
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized VEGF121, Human at 0.5μg/ml (100μl/well) on the plate can bind Human VEGF R1, His Tag. Test result was comparable to standard batch. Measured by a reporter gene assay using HEK293TKDRNFAT Cell line. The ED50 for this effect is< 8 ng/mL. | |
| Expression System | HEK293 | |
| Theoretical Molecular Weight | 14.07 kDa | |
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 15-25 kDa based on Bis-Tris PAGE result. | |
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | |
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. |
| Synonyms | VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
